SCHEMBL6284092

SCHEMBL6284092

CCOCc1nc2c(Oc3ccccc3)nc(C)cc2n1CCCCNS(C)(=O)=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 2/20 0.43
TSHR P16473 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 2/20 0.35
ALDH1A1 P00352 1/20 0.34
HTT P42858 1/20 0.33
RAB9A P51151 2/20 0.32
LMNA P02545 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 2/20 0.32
TLR8 Q9NR97 2/20 0.32
ATM Q13315 1/20 0.32
PPARG P37231 1/20 0.32
HRH1 P35367 1/20 0.32
KCNH2 Q12809 1/20 0.32
EPOR P19235 1/20 0.31
PLK1 P53350 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6096919 0.84 TLR8 (0.41) TLR7TSHRMEN1KMT2ARAB9A
SCHEMBL6095541 0.84 TLR7 (0.47) TLR7TSHRMEN1KMT2ATDP1
SCHEMBL6094799 0.82 TLR8 (0.46) TLR7TLR8
SCHEMBL6285069 0.82 TLR7 (0.48) TLR7TDP1TLR8
SCHEMBL4794829 0.79 MEN1 (0.46) TLR7TSHRMEN1KMT2AALDH1A1
SCHEMBL6779139 0.78 TLR7 (0.44) TLR7ALDH1A1TLR8
SCHEMBL6244056 0.77 TLR7 (0.42) TLR7TSHRMEN1KMT2AALDH1A1
SCHEMBL6774083 0.76 TLR7 (0.40) TLR7TLR8
SCHEMBL6784556 0.74 TLR7 (0.40) TLR7MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL6779163 0.73 SCN1A (0.44) TLR7ALDH1A1TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878719-B2 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2005-04-12 US disclosed
EP-1453829-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M Innovative Properties Company (US) 2004-09-08 EP disclosed
US-20040147533-A1 Sulfonamido substituted imidazopyridines 3M INNOVATIVE PROPERTIES COMPANY 2004-07-29 US disclosed
US-6696465-B2 INDUCING BIOSYNTHESIS OF CYTOKINES; VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2004-02-24 US disclosed
US-20040019076-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY 2004-01-29 US disclosed
WO-2003050117-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES 3M INNOVATIVE PROPERTIES COMPANY (US) 2003-06-19 WO disclosed
US-6525064-B1 Immune response modifiers; can induce the biosynthesis of various cytokines; 3M INNOVATIVE PROPERTIES COMPANY 2003-02-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147533-A1 Sulfonamido substituted imidazopyridines IRF3, EIF2AK2, MYD88 TLR7 52/4885TSHR 2325/4885MEN1 3535/4885
US-20040019076-A1 SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES IRF3, EIF2AK2, MYD88 TLR7 52/4885TSHR 2325/4885MEN1 3535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.